• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Warfarin-induced isolated spontaneous subarachnoid hemorrhage: Rare case report
CONCLUSION: Warfarin is rarely associated with isolated subarachnoid hemorrhage. This case highlights a young male patient with spontaneous SAH after warfarin therapy for acute ischemic stroke. Aneurysmal rupture and trauma should be excluded before a diagnosis of warfarin-induced SAH is made.PMID:36582886 | PMC:PMC9793204 | DOI:10.1016/j.amsu.2022.104946
Source: Annals of Medicine - December 30, 2022 Category: Internal Medicine Authors: Mohamed Sheikh Hassan Ahmet Bakir Bakar Ali Adam Nor Osman Sidow Abdiwahid Ahmed Ibrahim Ishak Ahmed Abdi Mohamud Mire Waberi Source Type: research

Associations Between Drug Treatments and the Risk of Aneurysmal Subarachnoid Hemorrhage: a Systematic Review and Meta-analysis
AbstractThere is increasing interest in drug therapy for preventing aneurysmal subarachnoid hemorrhage (aSAH). We aimed to comprehensively evaluate the association between drug use and the risk of aSAH. We searched PubMed and Scopus from the databases ’ inception until December 2021. Observational studies reporting the association between any drug therapy and aSAH were included. The odds ratios (ORs) for each drug used in aSAH were meta-analyzed with a random-effect model. According to the systematic review, 25 observational studies were eligib le for the present study. Four therapeutic purpose-based classes (e.g., lipid...
Source: Translational Stroke Research - October 15, 2022 Category: Neurology Source Type: research

Vitamin K Antagonist (Phenprocoumon) and Subarachnoid Hemorrhage: A Single-Center, Matched-Pair Analysis
ConclusionPatients with phenprocoumon treatment at the time of SAH are significantly older, admission status is worse, and 30-day mortality rates are significantly higher compared to patients without anticoagulant treatment. However, outcome at 6  months did not differ to the matched-pair control group but seems to be strongly associated with the underlying cardiovascular disease. Treatment of these patients is challenging and should be performed on an interdisciplinary base in each individual case. Careful decision-making regarding discont inuation and bridging of anticoagulation and close observation is mandatory.
Source: Neurocritical Care - October 27, 2019 Category: Neurology Source Type: research

Use of Non –Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review
Semin Thromb Hemost DOI: 10.1055/s-0037-1607436This observational study aimed to investigate the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with malignancy. A total of 76 patients (mean age: 73.2 ± 8.9; 28 females) with AF and malignancy treated with NOAC were included in the analysis. The mean CHA2DS2-VASc and HAS-BLED scores were 3.2 ± 1.2 and 2.2 ± 0.9, respectively. The study population was taking dabigatran 150 mg (25%) twice daily (BID), apixaban 5 mg BID (25%), dabigatran 110 mg BID (24%), rivaroxaban 20 mg (18%) once a da...
Source: Seminars in Thrombosis and Hemostasis - December 8, 2017 Category: Hematology Authors: Russo, Vincenzo Rago, Anna Papa, Andrea Antonio Meo, Federica Di Attena, Emilio Golino, Paolo D'Onofrio, Antonio Nigro, Gerardo Tags: Review Article Source Type: research